PHASE I STUDY ELIGIBILITY CRITERIA:\r\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI, olaparib, cediranib, or to other humanized monoclonal antibodies; known history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthma
PHASE II STUDY COHORT  OVARIAN CANCER ELIGIBILITY CRITERIA (MEDI+O, MEDI+C AND MEDI+O+C):\r\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI, olaparib, cediranib, or to other humanized monoclonal antibodies; known history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthma
PHASE II STUDY COHORT  TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI, olaparib or to other humanized monoclonal antibodies; known history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthma
PHASE II STUDY NON-SMALL CELL LUNG CANCER (COHORT ; MEDI+O AND MEDI+C) AND SMALL CELL LUNG CANCER (COHORT ; MEDI+O ONLY) ELIGIBILITY CRITERIA:\r\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI, olaparib, cediranib, or to other humanized monoclonal antibodies; known history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthma
PHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT  ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHistory of allergic reactions (known history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthma) attributed to compounds of similar chemical or biologic composition to MEDI, olaparib, or to other humanized monoclonal antibodies
PHASE II COLORECTAL CANCER COHORT  (MEDI+C ONLY):\r\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI, cediranib, or to other humanized monoclonal antibodies; known history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthma
